Familial neonatal SIDS revealing carnitine-acylcarnitine translocase deficiency by Nuoffer, Jean-Marc et al.
ORIGINAL PAPER
J.-M. Nuoer á P. de Lonlay á C. Costa á C.R. Roe á N. Chamoles á M. Brivet
J.M. Saudubray
Familial neonatal SIDS revealing carnitine-acylcarnitine
translocase de®ciency
Received: 13 April 1999 /Accepted: 26 August 1999
Abstract A patient with a severe phenotype of carnitine-acylcarnitine translocase defi-
ciency (CATR)(McKusick 212138) is reported. Prior to birth, a defect in b-oxidation was
suspected because of neonatal death of six siblings. Dietary treatment during neonatal
adaptation and the subsequent six months of life and a trial of carnitine supplementation
are reported. The rapidity with which long chain fatty acid metabolites can accumulate
and induce secondary carnitine deficiency within a few hours after birth in an infant with
CATR is noteworthy.
Conclusion High rates of glucose suppressed neonatal lipolysis in this infant, but did not
seem sucient to avoid secondary carnitine deficiency as in severe forms of CATR.
Therefore simultaneous use of insulin and glucose may be necessary to control neonatal
lipolysis. Carnitine supplementation and the possible adverse eects of MCT
systematically administrated, should be further assessed in patients with CATR.
Key words Long chain fatty acids á Medium chain fatty acids á Diet á Carnitine á
Beta-oxidation
Abbreviations CATR carnitine-acylcarnitine translocase deficiency á LCT long chain
triglycerides á MCT medium chain triglycerides á LCFA long chain fatty acid á NEFA
non esterified fatty acids á BW body weight á MRI magnetic resonance imaging á VEP
visual evoked potential á ERG electroretinogramm á GGT gamma glutamyl transferase
Introduction
Long chain fatty acid oxidation contributes substantially
to energy homeostasis, therefore defects of mitochon-
drial LCFA oxidation are serious, multisystemic and
life-threatening disorders. The clinical relevance of sec-
ondary carnitine deficiency and the question of carnitine
substitution in LCFA oxidation still remains contro-
versial [17]. Besides its use for conjugating acyl-groups,
carnitine-acylcarnitine translocase has a central role in
the so called ‘‘carnitine cycle’’ allowing acylcarnitine
esters to cross the inner mitochondrial membrane for
b-oxidation [17]. We report on a patient with CATR
defect, in whom a b-oxidation disorder was highly sus-
pected prior to birth because of the neonatal death of six
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siblings and describe the evolution and dietary treatment
from birth to death at 6 months of age. We also
emphasize the rapidity with which LCFA metabolites
accumulate at birth inducing secondary carnitine
deficiency within a few hours. Further we discuss a trial
with intravenous and oral carnitine supplementation.
Case report
The girl, was the eighth child, of healthy gypsy parents who are first
cousins. Only one girl is alive and healthy. Four children died
unexpectedly before day three and were considered SIDS. One
child died on day one with a hemorragic syndrome and severe
refractory bradycardia. Another sibling died following an over-
night fast at 24 h of life. Investigations revealed hypoketotic
hypoglycemia, hyperammonemia, C6–C10-dicarboxylic aciduria,
5-OH-hexanoic acid excretion and auriculo-ventricular block.
Necropsy showed a liver steatosis in both siblings.
A defect in b-oxidation was strongly suspected prior to birth in
the present patient, because of the suggestive family history. A
postnatal transfer to the pediatric hospital was planned. The child
was born at 38 weeks of gestation; with a birth weight of 2800 g,
length of 46 cm, head circumference of 33.8 cm. There was a mu-
cocutaneous bleeding syndrome; clinical examination was other-
wise normal. Glucose infusion and continuous gastric drip feeding
with glucose enriched skimmed milk, providing 14 mg/kg/min
glucose, in order to block lipolysis, was started at 4 hours of life,
after the child had received blood platelets. At arrival in our de-
partment at 10 hours of age laboratory studies revealed: lactate
6 mmol/l (N: 0.63–2.44), ammonia 128 lmol/l (N: <40 lmol/l),
NEFA 0.64 mmol/l (N: 0.3–0.7 mmol/l), creatine kinase 574 IU/l
(N: <300 U/I). Plasma and urine amino acid as well as urine or-
ganic acid analyses and blood glucose were normal. Cardiac in-
vestigation showed mild abnormalities of repolarisation and
moderate left ventricular hypertrophy with good systolic function.
On day three the CATR defect was confirmed and laboratory
studies showed: normal glucose, lactate, ammonia and very low
NEFA (<0.02 mmol/l), suggesting indeed a total suppression of
lipolysis. On day four a MCT based formula (Portagen, Mead
Johnson) was delivered by continuous nasogastric tube feeding,
supplying in total 60 g carbohydrates (15 mg/kg/min), 5 g protein,
4.5 g MCT and 0.5 g LCT providing 120 kcal/kg BW. At 2 weeks
an accidental fast, due to an interruption of the continuous naso-
gastric tube feeding of 14 hours, occurred. The child presented with
hypothermia, hypotonia, pallor and coma, hypoglycemia, lac-
tacidemia (5.4 mmol/l), hyperammonemia (117 lmol/l). Organic
acid analyses showed C6 to C10-dicarboxylic acids, 4-hydroxy
phenyllactic and 4-hydroxy phenylpyruvic acid excretion without
ketones. EKG and echocardiography remained normal. The clini-
cal and biochemical abnormalities normalized within 48 hours.
Further complications were the mucocutaneous bleeding syn-
drome, oesophagitis, repeated bacterial infections and unexplained
arterial hypertension controlled by nifedipin. An exhaustive he-
matological investigation (coagulation, in vitro platelet aggregation
test, ADP release, platelet membrane receptors for VWF and fi-
brinogen) pointed to a platelet aggregation disorder. Glanzmann
thrombasthenia, known in this family, was excluded, because she
was found to be heterozygous. The diet was regularly maintained,
keeping glucose intake at 10–13 mg/kg/min, protein 2 g/kg/d,
MCT 2–3 g/kg/d, providing 100–120 kcal/kg/d, without carnitine
supplementation for the first two months. Adequate feeding was
ensured by gastrostomy and a port-a-cath. Repeated attempts to
divide continuous nasogastric tube feeding into individual meals
failed, causing ileus-like symptoms. At two months, plasma carni-
tine was very low (total 6 lM and free 3 lM) and a trial with iv
carnitine (200 mg every 8 hours for four days) was started, because
of the suspected relation of low carnitine and feeding intolerance.
Later on, oral carnitine was maintained at the same dosage, with-
out improvement of feeding tolerance. At five months psychomotor
development, brain MRI, VEP, ERG and cardiac function were
normal and growth followed the 10th centile. Hepatomegaly de-
veloped after five months, with a slight elevation of alkaline
phosphatase (300–700 U/L), GGT (40–250 U/L), and conjugated
bilirubin (3–50 lmol/l). The patient died unexpectedly at 6 months
of age from a staphylococcal port-a-cath septicemia with exacer-
bation of the hemorrhagic mucocutaneous syndrome. Necropsy
was refused by the parents.
Methods
Overall b-oxidation, carnitine-acylcarnitine translocase, carnitine
acetyltransferase and the pyruvate oxidase system were measured
in lymphocytes and fibroblasts [3, 5, 15]. Acylcarnitines were reg-
ularity monitored from blood samples on standard Guthrie cards
by tandem mass spectrometry [11]. Samples from day 1 to 76 were
analyzed (Ch Roe and DS Millington) at Duke University, USA
and samples from day 85 on (N Chamoles) in Buenos Aires,
Argentina.
Results
Overall b-oxidation of palmitate in lymphocytes and fi-
broblasts was severely depressed, CATR was profoundly
deficient with almost no residual activity (Table 1).
Mutation analysis revealed a homozygous C558T tran-
sition in the CATR cDNA, resulting in a premature stop
codon (R166X) [8]. Selected acylcarnitine profiles of
Table 1 b-oxidation flux and
translocase activity Lymphocytes Fibroblasts
Patient Controls (n = 40) Patient Controls (n = 25)
(Range) (Range)
Flux from 2.42 3.53  0.81 6.30 4.89  1.74
[1-14C]octanoate* (2.23–6.37) (2.25–8.89)
Flux from 0.29 6.12  1.28 0.30 9.39  1.70
[9,10-3H]palmitate  (4.00–9.20) (6.75–13.4)
Translocase activity§ 0.025 1.16  0.16 0.00 1.47  0.20
(0.82–1.49) (0.93–2.00)
Pyruvate oxidase and carnitine acetyl transferase activities were normal (data not shown). Values for
control subjects are mean  SD, with ranges in parenthesis
*Values are expressed as nmol of 14CO2 released/hour/mg of protein
 Values are expressed as nmol of 3H2O released/hour/mg of protein
§ Values are expressed as nmol/minute/mg of protein
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interest are depicted (Figure 1). At birth the profile
showed grossly increased palmitoylcarnitine which nor-
malized on day four as did other signs of metabolic
decompensation. Changes in carnitine concentration
during the neonatal period, at MCT introduction and on
iv and oral carnitine are shown in Figure 1. On iv car-
nitine short-, medium- and long-chain acylcarnitine in-
creased twenty, thirty and sevenfold respectively. O
carnitine, secondary carnitine deficiency developed
within a few days.
Discussion
CATR deficiency is a disorder of LCFA b-oxidation.
Most reported patients were seen within 2 days after
birth with hypoglycemia, hyperammonia, heart beat
disorder or sudden death [3, 4, 6, 9, 12–15, 18]. In the
present reported family, six siblings died within the first
days of life, four were considered as neonatal SIDS.
Although the term SIDS [20] is not entirely appropriate,
one should be aware that patients with defect in b-oxi-
dation are easily mistaken for SIDS if no histologic ex-
amination of liver and cardiac muscle is done [1]. As
energy metabolism in neonates is mostly based on high
palmitate flux and fatty acid b-oxidation [2], the degree
of neonatal lipolysis may be an important determinant
of clinical outcome in severe forms of CATR deficiency.
Despite glucose infusion started at 4 hours of life, our
patient presented slight signs of biochemical decom-
pensation, while free fatty acids were 0.64 mmol/l. The
carbohydrate enriched, LCT free diet however further
suppressed neonatal lipolysis, resulting in prompt nor-
malization of lactate, ammonia and palmitoylcarnitine
within the first days of life. An even better control of
neonatal lipolysis may be achieved with simultaneous
use of insulin and glucose. Plasma carnitine deficiency
developed within few days despite continuous gastric
drip feeding and very low NEFA. Carnitine deficiency is
an usual finding in b-oxidation deficient patients. Car-
nitine supplementation in LCFA oxidation defects re-
mains however controversial [17]. Arrhythmogenesis
induced by experimental myocardial ischemia has been
shown to be related to long-chain acylcarnitine accu-
mulation [7], however this observation has been more
recently questioned [10]. On the other hand esterification
with carnitine of potentially toxic acyl-CoA intermedi-
ates resulting from lipolysis and MCT enriched diet may
be the only way of detoxification. Indeed there is some
evidence that in CATR decanoyl (C10) and dodecanoyl
(C12) oxidation is also reduced [17]. This may be due to
the substrate specificity of long chain acyl-CoA synthase
ranging from C10–C20 saturated fatty acids [19]. Since
this enzyme is located at the outer mitochondrial mem-
brane, C10- and C12-CoA will not be able to enter the
mitochondria in the absence of CATR. As in MCT oil
the fatty acid moieties C10 or longer account for 41.5%
of total fatty acids, MCT supplementation may lead to
the accumulation of C10–C12 acyl-CoA. Although C10–
C12 oxidation was not directly investigated in the pres-
ent patient, a deficient oxidation was indirectly sug-
Fig. 1 Special events are indicated with an arrow. C2 = acetyl-
carnitine, C8 = octanoylcarnitine, C10 = decanoylcarnitine, C16 =
palmitoylcarnitine. Carn tot and free = total and free plasma
carnitine concentrations in lM measured by conventional method
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gested by the increase of C10/C8 acylcarnitine ratio
from 1 to 1.6. Similarly as in organic aciduria, this could
be a rational for carnitine substitution [16]. Indeed car-
nitine supplementation was well supported with no
cardiac side eects as already observed in 2 previously
treated CATR patients [14, 18]. Intravenous carnitine
supplementation rose all acylcarnitine species and free
carnitine to supraphysiological concentrations as it is
observed after carnitine substitution in carnitine de-
pleted states (Roe, personal communication). High rates
of glucose did suppress neonatal lipolysis but did not
avoid carnitine depletion in our patients. Carnitine
supplementation should be systematically tried and
further assessed in patients with CATR. In addition the
usefulness and the safety of MCT supplementation in
CATR deficiency should be carefully investigated. The
early neonatal presentation with sudden unexplained
death in previous patients and our observation further
underline the importance of prenatal diagnosis for
families at risk.
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